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Abstract
We characterized the uptake of carnitine in brush-border membrane (BBM) and basolateral membrane (BLM) vesicles,
isolated from mouse kidney and intestine. In kidney, carnitine uptake was Na-dependent, showed a definite overshoot and
was saturable for both membranes, but for intestine, it was Na-dependent only in BLM. The uptake was temperature-
dependent in BLM of both kidney and intestine. The BBM transporter in kidney had a high affinity for carnitine: apparent
Km = 18.7 WM; Vmax = 7.85 pmol/mg protein/s. In kidney BLM, similar characteristics were obtained: apparent Km = 11.5
WM and Vmax = 3.76 pmol/mg protein/s. The carnitine uptake by both membranes was not affected within the physiological
pH 6.5^8.5. Tetraethylammonium, verapamil, valproate and pyrilamine significantly inhibited the carnitine uptake by BBM
but not by BLM. By Western blot analysis, the OCTN2 (a Na-dependent high-affinity carnitine transporter) was localized
in the kidney BBM, and not in BLM. Strong OCTN2 expression was observed in kidney and skeletal muscle, with no
expression in intestine in accordance with our functional study. We conclude that different polarized carnitine transporters
exist in kidney BBM and BLM. L-Carnitine uptake by mouse renal BBM vesicles involves a carrier-mediated system that is
Na-dependent and is inhibited significantly by specific drugs. The BBM transporter is likely to be OCTN2 as indicated by a
strong reactivity with the anti-OCTN2 polyclonal antibody. ß 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
Carnitine, L-hydroxy Q-N-trimethylammonium bu-
tyrate, is an essential cofactor for the transfer of
long-chain fatty acids from the cytosol into mito-
chondria for subsequent L-oxidation. Another well
established function of carnitine is the maintenance
of the cellular coenzyme-A pool [1]. In humans, L-
carnitine is obtained from dietary sources, primarily
meat and dairy products, and produced endoge-
nously from the amino acids lysine and methionine,
with both sources contributing to plasma and tissue
levels.
The major site of L-carnitine absorption is the
small intestine but the mechanism of intestinal up-
take of L-carnitine is unclear. Earlier studies using
intact intestinal tissue preparations suggested that
intestinal L-carnitine uptake occurred by a carrier-
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mediated process [2], but in a subsequent study us-
ing rat intestinal brush-border membrane (BBM)
vesicles, it was concluded that the uptake process
is a passive di¡usion [3]. Thus, the mechanism of
the L-carnitine uptake process remains controver-
sial. More recently, McCloud et al. [4] showed that
the L-carnitine uptake by intestinal epithelial cells
(Caco-2) involves a carrier-mediated system (Km
of 45 WM) that is temperature-, Na- and energy-
dependent.
Dietary intake and carnitine biosynthesis are re-
sponsible to maintain the carnitine body stores in
mammals [5]. Carnitine is eliminated as free carnitine
or acylcarnitine almost exclusively by the kidneys,
where it is ¢ltered and reabsorbed by s 95% in the
proximal tubule [1]. The kidney has in fact a crucial
role in homeostatic regulation of carnitine concentra-
tion in body £uids. The carnitine reabsorption ap-
pears to be regulated such that normal plasma car-
nitine concentration (30^90 WM) is maintained
without signi¢cant loss of carnitine in the urine [6].
When carnitine reabsorption is impaired, e.g. in pa-
tients with primary carnitine de¢ciency [7], the plas-
ma and tissue carnitine concentrations decrease and
clinical symptoms of carnitine de¢ciency can devel-
op, underlining the importance of the renal carnitine
transport system. Solute reabsorption by the kidney
is a multistep process implying translocation of
the substrate across the luminal and removal to the
circulation by passage across the anti-luminal
membrane (basolateral membrane, BLM) [8]. For
carnitine, the renal transport system has been char-
acterized in rat kidney BBM vesicles [8,9]. These
studies revealed Na-dependent, saturable transport
of L-carnitine, with Km of 55 WM [8] and two trans-
port systems with Km values of 17 WM and 15 mM
[9]. The transport could be inhibited by structural
analogues such as D-carnitine, butyrobetaine, L-ace-
tyl-carnitine but not by glycinebetaine. No study of
carnitine transport in mouse apical or BLM vesicles
has been reported.
De¢ciency states occur when dietary sources are
inadequate (such as in vegetarian diets), gastrointes-
tinal absorption is decreased, renal losses are exces-
sive, or endogenous production is inadequate second-
ary to an enzyme de¢ciency. Primary systemic
carnitine de¢ciency (SCD; OMIM 212140) in human
patients causes severe pathological symptoms such as
cardiomyopathy, muscle weakness, fasting hypogly-
cemia and sudden death [10,11]. It is also character-
ized by excessive losses of intestinal and urinary car-
nitine [12]. SCD is transmitted in an autosomal
recessive manner. It is caused by mutations in the
OCTN2 gene which encodes a carnitine and organic
cation transporter (OCT) cloned recently [13,14]. The
OCTN2 protein has 557 amino acids with 12 puta-
tive transmembrane domains. Until now, three trans-
porters of carnitine have been identi¢ed, and called
OCTN1, OCTN2 and OCTN3. They belong to the
OCT family and have di¡erent characteristics,
namely a⁄nity and capacity for carnitine transport,
energization of transport, and sensitivity to inhibi-
tors. These transporters are expressed in several tis-
sues, but the precise intracellular localization is un-
known.
A mouse model known as jvs or ‘juvenile visceral
steatosis’ shows the same characteristics as the hu-
man SCD [15,16]. The homozygous jvs mutants show
a microvesicular fatty in¢ltration of the viscera, and
a signi¢cant cardiomyopathy. These mice have low
levels of carnitine in the serum, the liver and the
skeletal and cardiac muscles. De¢ciency of carnitine
transport has been demonstrated in the renal tubules,
¢broblasts and the hepatocytes (absence of the high-
a⁄nity transporter, [17]). Recently, it has been con-
¢rmed that the gene for the mouse carnitine trans-
porter OCTN2 (located on chromosome 11) is mu-
tated in the jvs strain. In this mutation, leucine 352 is
changed to arginine in the sixth transmembrane do-
main of OCTN2 [18].
A study of the physiology of L-carnitine transport
in mice is important to understand the nature of
human SCD and its mouse counterpart in the jvs
model and to con¢rm the apical and/or BLM local-
ization of OCTN2 in both kidney and small intestine.
Our hypothesis is that di¡erent polarized carnitine
transporters may exist in BBM and BLM. The ra-
tionale is based largely on analogy with other trans-
port systems, such as renal K-ketoglutarate trans-
porter [19] and lysine transporter implicated in
lysinuric protein intolerance [20]. The properties of
the two steps in carnitine absorption, transport
across the renal and intestinal BBM and BLM,
were evaluated by measuring the uptake of labeled
substrate using puri¢ed membrane vesicles. Our re-
sults show that L-carnitine uptake by mouse renal
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BBM vesicles involves a Na-dependent carrier that
is likely to be OCTN2.
2. Materials and methods
2.1. Materials
L-[Methyl-3H]carnitine hydrochloride (82 Ci/
mmol) was purchased from Amersham Pharmacia
Biotech (Buckinghamshire, UK). D-[1-3H(N)]Glucose
(30 Ci/mmol) was purchased from New England Nu-
clear (Guelph, Canada). The drugs tetraethylammo-
nium (TEA), valproate, verapamil and pyrilamine
and the other reagents were obtained from Sigma-
Aldrich Chemicals (Oakville, Canada).
2.2. Membrane vesicle preparation
BBM vesicles were isolated from the renal cortex
and the proximal half of the small intestine of mice
(strain C57-BL/6J), by the Mg2 precipitation meth-
od described by Hauser et al. [21]. Renal cortex
and intestine were immediately removed and rinsed
with ice-cold 0.9% NaCl solution. BBM from renal
cortices and intestinal mucosal scrapings were pre-
pared as previously described [22]. BLM vesicles
from renal cortices and intestinal mucosal scrap-
ings were prepared by a Percoll density gradient
centrifugation method as described by Edwards et
al. [19].
2.3. Biochemical assays
The protein determination was done by the meth-
od of Lowry et al. [23] using serum albumin as a
standard. The degree of purity of membranes was
assessed by measuring the enrichment of marker en-
zymes for the BBM, alkaline phosphatase [24], and
for the BLM, Na,K-ATPase [25]. For the BBM,
the relative enrichment of alkaline phosphatase over
the original homogenate was 7.5 and 8 for intestine
and kidney, respectively. For the BLM, the enrich-
ment factor of Na,K-ATPase was 8 for intestine,
and 8.5 for kidney. These values compare closely to
those obtained in rabbits [26] and are generally con-
sidered as satisfactory.
2.4. Uptake studies
Uptake of [3H]carnitine was done manually with
manifold using cellulose nitrate ¢lters, 0.65 Wm pore
size from Sartorius, Go«ttingen, Germany, or mea-
sured by a rapid ¢ltration method using the FSRFA
(fast sampling rapid ¢ltration apparatus) as de-
scribed by Malo and Berteloot [27]. BBM and
BLM vesicles were usually resuspended in a ¢nal
concentration of 15^20 mg of protein/ml in the ¢nal
resuspension bu¡er (50 mM Tris^HEPES (N-2-hy-
droxyethylpiperazine-NP-2-ethanesulfonic acid), 0.1
mM MgSO4, 250 mM KCl, 125 mM mannitol, pH
7.5), and 20 Wl/0.5 ml incubation medium (¢nal con-
centrations: 50 mM Tris^HEPES, 0.1 mM MgSO4,
100 mM KCl, 150 mM NaCl, 125 mM, mannitol, pH
7.5) was used. The sodium-dependent uptake was
determined by subtracting the sodium-independent
(KCl only, 250 mM) uptake from the sodium-depen-
dent (KCl 100 mM+NaCl 150 mM) uptake. (A)
Manual uptake: L-[3H]carnitine at 50 WM was added
to the incubation medium and the reaction started by
addition of membrane vesicles. After di¡erent incu-
bation times, the uptake was stopped by adding 2 ml
of ice-cold stop solution (cold resuspension bu¡er);
the ¢lters were washed three times with 2 ml ice-cold
stop solution before radioactivity counting. (B) Up-
take with FSRFA: this apparatus allows for sam-
pling of up to 18 aliquots from the same incubation
mixture and fully automates the sequence of vesicle
injection and mixing with the incubation medium,
samplings, washings, and ¢ltrations. Carnitine up-
take as a function of time was determined using
nine aliquots of 50 Wl each at di¡erent time intervals
and processed as described in [27]. For both ap-
proaches, corrections were made for [3H]carnitine
bound to the ¢lters in the absence of vesicles which
was always 6 0.1% of added counts; the functional
integrity of BBM vesicles was veri¢ed by testing D-
glucose uptake by renal and intestinal preparations
(vi = 2.63 þ 0.3 pmol/mg protein/s for kidney, and
vi = 2.15 þ 0.24 pmol/mg protein/s for intestine).
2.5. Assays with xenobiotic inhibitors
Membrane vesicles were prepared as described
above. The incubation medium contained (¢nal con-
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centrations) 50 WM L-[3H]carnitine (1 WCi per assay),
50 mM Tris^HEPES, 0.1 mM MgSO4, 100 mM KCl,
150 mM NaCl, 125 mM mannitol, pH 7.5, and 500
WM of the xenobiotic. Transport was started by add-
ing 6 Wl of membrane suspension to 48 Wl of pre-
heated incubation medium (37‡C). The reaction
was stopped after 8 s for BBM, and 4 s for BLM.
2.6. Membrane localization and tissue distribution
study by Western blot analysis
Rabbit polyclonal antibodies were raised against
a synthesized polypeptide of mouse OCTN2
through Research Genetics, Inc. (Huntsville AL,
USA). The amino acid sequence used was
QWQIQSQTRMQKDGEESPT corresponding to
amino acids 532^550 of OCTN2. Mouse tissues
were isolated and homogenized in 4 ml bu¡er con-
taining 10 mM Tris^HCl and 50 mM mannitol (pH
7.4) using a polytron homogenizer. The solution was
then dispersed ultrasonically. After addition of sam-
ple bu¡er 2U (4% sodium dodecyl phosphate
(SDS), 20% glycerol, 200 mM dithiothreitol, 120
mM Tris, pH 6.8, and 0.002% bromophenol blue)
to the tissue homogenate or to the membrane
vesicles, the solution was mixed, the proteins were
denatured in a boiling water bath for 5 min and
used for Western blot analysis. The sample was sep-
arated by 7.5% SDS^polyacrylamide gel electropho-
resis (SDS^PAGE) and proteins were transferred to
polyvinylidene di£uoride membrane Immobilon
(Millipore, Bedford, MA, USA) which was incu-
bated in phosphate-bu¡ered saline (PBS) bu¡er
(150 mM NaCl, 2.5 mM KCl, 5 mM Na2HPO4,
1.5 mM KH2PO4) containing 0.02% sodium azide
and 12% skim milk. The membrane was incubated
with polyclonal anti-peptide antibody (in PBS bu¡er
containing 0.02% sodium azide and 1% bovine se-
rum albumin) overnight, rinsed with the above bu¡-
er without skim milk (but with 0.1% Tween 20), and
incubated with secondary antibody (goat anti-rabbit
IgG, horseradish peroxidase-linked whole antibody,
Sigma, St. Louis, MO, USA). The membrane was
washed as before and the proteins were detected
by a chemiluminescence detection method using
BM Chemiluminescence ELISA Substrate (POD)
(Boehringer Mannheim, Laval, QC, Canada). The
molecular weights were estimated by using pre-
stained SDS^PAGE standards, broad range (Bio-
Rad Laboratories, Hercules, CA, USA).
3. Results
3.1. Stability of BBM and BLM vesicles
Since there have been reports on the instability of
BBM in rabbits and rats [28] and since uptake ex-
periments usually last for a few hours, we have ¢rst
veri¢ed the stability of both mice BBM and BLM
vesicles by measuring the initial rates of 50 WM L-
carnitine uptake after 10, 20, 40, 60 and 120 min (not
shown) after thawing membrane vesicles from liquid
nitrogen. In BBM, the initial rates of L-carnitine
transport remained constant for 10 min, and then
decreased abruptly to 60%. In BLM, the L-carnitine
transport remained constant for 60 min, and de-
creased later on. All experiments reported in the fol-
lowing studies have been performed on both BBM
and BLM within 10 min after thawing from liquid
nitrogen, as during this period, both these prepara-
tions would remain stable.
Fig. 1. Relationship between initial rates of L-carnitine uptake
by renal BBM (squares) and renal BLM (circles) and membrane
protein concentrations. Vesicles were prepared as described
under Section 2. The initial rates of L-carnitine uptake have
been determined at 37‡C over the linear portion of the uptake
time (8 s for BBM and 3 s for BLM, see Fig. 2). When not
shown, the error bars were smaller than the symbols used. Lin-
ear regression analysis over the data points gave a correlation
coe⁄cient of 0.987 and 0.974 for BBM and BLM, respectively
(n = 2 determinations).
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3.2. Linearity of L-carnitine uptake with protein
concentrations
Renal BBM and BLM vesicles were resuspended
at di¡erent protein concentrations ranging from 4 to
30 mg per ml. As demonstrated in Fig. 1, the initial
rates of transport determined at a 50 WM L-carnitine
concentration were linear over this range of protein
concentrations for both membranes. All the follow-
ing experiments have been performed using concen-
trations of 15^20 mg of BBM or BLM proteins per
ml of resuspension medium.
3.3. Time courses of L-carnitine uptake by renal BBM
and BLM vesicles in mice using the FSRFA
Fig. 2A,B depicts the initial rate of carnitine up-
take by renal BBM and BLM vesicles. In BBM
vesicles, an inwardly directed 150 mM Na gradient
caused a large stimulation of L-[3H]carnitine uptake
relative to that observed in the absence of Na (Fig.
2A). The uptake was linear with time for 10 s (inset,
vi = 0.33 þ 0.05 pmol/mg protein/s) and showed an
overshoot at 20 s with a maximal accumulation of
5.2 pmol/mg protein. In BLM vesicles, the uptake of
L-[3H]carnitine was also much higher in the presence
of a Na gradient, but was linear only up to 4 s
(inset, vi = 0.3 þ 0.02 pmol/mg protein/s) with a max-
imal accumulation of 1.2 pmol/mg protein, at the
peak of the overshoot (Fig. 2B). These results indi-
cated a Na-coupled carnitine transport in both
membranes.
3.4. Temperature dependency of L-carnitine uptake by
renal BLM
Carnitine uptake by renal BLM was very fast. In
order to slow down the carnitine uptake, we deter-
Fig. 2. Time course and Na dependency of L-carnitine transport by mouse renal BBM (A) and BLM (B) at 37‡C. L-[3H]Carnitine
uptake was determined using the FSRFA, as described under Section 2. The incubation medium contained (¢nal concentrations) 50
WM L-[3H]carnitine (1 WCi per assay), 125 mM mannitol, 50 mM HEPES adjusted with Tris to pH 7.5, 100 mM KCl and 150 mM
NaCl (solid symbols) or 150 mM KCl (open symbols). Results are the mean þ S.D. from three di¡erent membrane preparations.
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mined the initial rate of carnitine uptake at two
di¡erent temperatures, 37‡C and 25‡C. At 25‡C,
the uptake was linear with time for 6 s (inset,
vi = 0.21 þ 0.01 pmol/mg protein/s), showed an over-
shoot at 8 s (Fig. 3) and was much higher in the
presence of a Na gradient (data not shown). Fur-
ther experiments with renal BLM were performed at
25‡C.
3.5. Kinetics of carnitine uptake by renal BBM and
BLM vesicles
To determine kinetic parameters for Na-depen-
dent carnitine uptake by renal BBM and BLM
vesicles in mice, the initial rates of L-carnitine uptake
were determined at di¡erent concentrations of unla-
beled substrate (Fig. 4A,B). The kinetic parameters
calculated by the Michaelis^Menten equation for one
transport site were determined as described in [27],
and were similar for the two membrane preparations.
Fig. 5. E¡ect of extravesicular pH and xenobiotics on L-carnitine uptake by renal BBM (¢lled bars) and BLM (open bars). (A) The
intravesicular pH was kept at pH 7.5 and the uptake medium pH was varied from 6.5 to 8.5. Initial rates of uptake were measured in
the presence of a Na gradient as described in Fig. 4. Results are the mean þ S.D. from three di¡erent experiments. (B) E¡ect of
xenobiotics on L-carnitine transport by renal BBM and BLM. Membrane vesicles were incubated with 500 WM of each xenobiotic. Ini-
tial rates of carnitine uptake were measured in the presence of a Na gradient as described in Fig. 4. Results are the mean þ S.D.
from three di¡erent experiments.
Fig. 4. Kinetics of Na-dependent L-carnitine transport by renal
BBM (A) and BLM (B) vesicles. Initial rates of L-carnitine up-
take into the membrane vesicles were measured after 8 s of in-
cubation at 37‡C in BBM, and after 5 s of incubation at 25‡C
in BLM, in the presence of a Na gradient as described in Fig.
2. Carnitine concentrations are given on the abscissa. Results
are the mean þ S.D. from two di¡erent experiments.
Fig. 3. Temperature dependency of L-carnitine transport by
mouse renal BLM. Uptake was carried out at two tempera-
tures: 37‡C (circles) and 25‡C (triangles). Conditions and proce-
dures are similar to those described in Fig. 2, and under Sec-
tion 2. Results are the mean þ S.D. from three di¡erent
experiments.
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The apparent a⁄nity (Km) of the BBM transporter
for carnitine was 18.7 þ 2.4 WM with a maximum
transport rate (Vmax) of 7.85 þ 0.82 pmol/mg pro-
tein/s. Likewise, in BLM vesicles, the apparent Km
was 11.5 þ 1.8 WM and Vmax was 3.76 þ 0.66 pmol/mg
protein/s.
3.6. E¡ect of extravesicular pH
The e¡ect of varying the extravesicular pH on re-
nal BBM and BLM carnitine uptake was examined
while keeping the intravesicular pH at 7.5. We found
that changing extravesicular pH from 7.5 to either
6.5 or 8.5 did not signi¢cantly a¡ect BBM and
BLM carnitine uptake (Fig. 5A).
3.7. E¡ect of xenobiotics on L-carnitine transport by
membrane vesicles
The ability of some drugs interacting with OCTN2
[29,30] to inhibit carnitine transport by mouse renal
BBM and BLM was investigated (Fig. 5B). While
TEA, valproate, verapamil and pyrilamine had no
e¡ect on the initial rate of carnitine uptake by renal
BLM, these compounds inhibited signi¢cantly (inhi-
bition between 27% and 54%) carnitine transport by
renal BBM.
3.8. Renal membrane localization and tissue
distribution of OCTN2
The mouse renal membrane localization of
OCTN2 was investigated by Western blot (in view
of the importance of kidney in the secretion and
reabsorption of drugs, xenobiotics, and organic en-
dogenous compounds, and because OCTN2 is better
expressed in kidney). The BBM and BLM were iso-
lated from mouse renal cortex and probed with the
polyclonal antibodies. The mouse OCTN2-speci¢c
antibody labeled protein at the BBM with an appar-
ent molecular mass of 70^80 kDa (Fig. 6A). BLM
showed no immunoreactivity for the antibody (Fig.
6A).
The tissue distribution of OCTN2 was also deter-
mined by Western blot analyses (Fig. 6C). The poly-
clonal antibodies recognized proteins of 70 and/or 80
kDa in immunoblot of homogenate proteins from
various tissues. Expression pro¢le of OCTN2 protein
Fig. 7. Time course and temperature dependency of Na-depen-
dent L-carnitine transport by mouse intestinal membrane
vesicles. Carnitine uptake by BBM (squares) (vi = 0.024 pmol/
mg protein/s) and BLM (¢lled lozenges) (vi = 0.36 þ 0.01 pmol/
mg protein/s) at 37‡C was measured in the presence of a Na
gradient. Carnitine uptake by mouse intestinal BLM was also
measured at 25‡C (open lozenges) (vi = 0.22 þ 0.02 pmol/mg pro-
tein/s) in the presence of a Na gradient. Conditions and proce-
dures are similar to those described in Fig. 2, and under Sec-
tion 2. Each point is the mean þ S.D. of three di¡erent
experiments.
Fig. 6. Membrane localization in kidney (A), intestine (B) and
tissue distribution (C) of OCTN2 by Western blot analysis.
Anti-peptide antibody speci¢c to OCTN2 was used. Renal or
intestinal BBM and BLM from mouse (isolated as described
under Section 2) (30 Wg/lane) and tissue homogenates prepared
from mouse kidney, liver, heart, lung, brain, skeletal muscle,
testis and intestine (30 Wg protein each) were separated on
SDS^polyacrylamide gels (7.5%). To develop the Western blot,
a peroxidase-coupled secondary antibody was used, and the re-
action was visualized by chemiluminescence. Molecular weights
(kDa) are shown on the left side.
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was broad (expression in kidney, liver, heart and
skeletal muscle, but not in brain, lung, intestine
and testis), and strong in skeletal muscle.
3.9. Carnitine uptake by intestinal BBM and BLM
vesicles
Similar studies as described for kidney were done
for intestine. The purity, stability and functional in-
tegrity of intestinal membrane vesicles were compa-
rable to those found in kidney (data not shown). The
time courses of L-carnitine uptake and the in£uence
of Na and temperature (37‡C and 25‡C) on carni-
tine transport by intestinal BBM and BLM were an-
alyzed. In the presence of Na, carnitine uptake was
di¡erent in the two membranes (Fig. 7). In intestinal
BBM vesicles (¢lled squares), carnitine accumulation
showed very low values (Fig. 7) while in BLM
vesicles (¢lled lozenges), carnitine uptake was linear
up to 4 s in the presence of a Na gradient (Fig. 7).
In the absence of Na, there is no carnitine uptake in
both membranes (not shown). The temperature e¡ect
showed that at 25‡C (Fig. 7, open lozenges), the up-
take was linear with time for 6 s. Moreover, the
carnitine uptake by intestinal BLM was pH-inde-
pendent since there were no signi¢cant di¡erences
in uptake values when extravesicular pH was varied
between 6.5 and 8.5 (Fig. 8). Elsewhere, intestinal
membrane localization studied by Western blot
showed an absence of immunoreactivity between
OCTN2 antibodies and both BBM and BLM (Fig.
6B).
4. Discussion
We examined, for the ¢rst time in mice, the char-
acteristics of carnitine uptake into BBM and BLM
vesicles from renal cortices and intestinal mucosal
scrapings. The use of isolated membrane vesicles
avoided the interference of carnitine metabolism or
carnitine uptake by other cellular compartments. We
investigated, moreover, the localization at the lumi-
nal or basolateral plasma membrane of a recently
cloned carnitine transporter, OCTN2, to understand
its function in kidney and intestine.
4.1. Characterization of L-carnitine transport in the
mouse kidney
In the mouse kidney, we found that there is a
Na-dependent carnitine uptake across both BBM
and BLM membranes with similar kinetic properties.
These parameters were close to those found in rat
BBM by Rebouche and Mack [8] and to the carnitine
transport high-a⁄nity system found in rat BBM by
Stieger et al. [9]. In our studies the alteration of ex-
travesicular pH between 6.5 and 8.5 had a minimal
e¡ect on carnitine uptake by both BBM and BLM
vesicles in mouse kidney. The examination of the
extravesicular e¡ect of pH on BBM carnitine uptake
is physiologically relevant because the in vivo pH of
the proximal tubular £uid (equivalent to the extra-
vesicular pH in the mostly right-side-out BBM
vesicles) decreases along the proximal tubule, from
7.4 in the early proximal convoluted tubule to about
6.5 in the late proximal straight tubule [8].
Although the qualitative aspects of carnitine trans-
port were similar in the two membrane preparations
from kidney, there were some di¡erences in the time
courses of carnitine uptake. First, under Na gra-
dient conditions and at 37‡C, the period of linearity
was shorter (4 s) in BLM vesicles than in BBM
vesicles (10 s) which may be explained by a faster
dissipation of the Na gradient. Second, the initial
rate of carnitine uptake was more than two times
higher in BBM than in BLM vesicles (Fig. 2A,B)
which may re£ect a higher concentration of carrier
molecules within the apical membrane. The substrate
speci¢city of the transporter (s) was also di¡erent in
the two kidney vesicle preparations. The organic cat-
ions TEA (nicotinic, cholinergic antagonist), verapa-
Fig. 8. E¡ect of extravesicular pH on L-carnitine uptake by in-
testinal BLM. Experimental conditions are similar to those de-
scribed in Fig. 5A.
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mil (anti-angina, anti-arrhythmic), pyrilamine (anti-
histaminic), and the organic anion valproate (anti-
convulsant, anti-epileptic) inhibited signi¢cantly car-
nitine uptake by BBM but not by BLM. This di¡er-
ential e¡ect of various xenobiotics on carnitine up-
take by renal membrane vesicles indicates clearly that
there are di¡erent carnitine transporters in BBM and
BLM from kidney. The lack of pH e¡ect on carnitine
transport by renal membrane vesicles suggests that
the transport mechanism is not a cotransport of car-
nitine/H in both mouse kidney BBM and BLM.
This characteristic excludes an involvement of
OCTN1 since this low-a⁄nity transporter is pH-de-
pendent in human [31] and rat [32] (although
rOCTN1 does not mediate carnitine transport to
any signi¢cant level) while pH dependency for mouse
OCTN1 has not been previously tested [33]. The Na
dependency of carnitine transport in renal BBM and
BLM vesicles excludes the implication of the very
recently cloned mouse Na-independent OCTN3
[33].
Ohashi et al. [30] have tested the e¡ect of various
xenobiotics on kidney cells (HEK, human epithelial
kidney) transfected with the carnitine transporter
hOCTN2 and found a signi¢cant inhibition by
TEA, valproate, verapamil and pyrilamine. These
data suggested that carnitine transport in mouse re-
nal BBM implicates OCTN2, a physiologically im-
portant Na-dependent high-a⁄nity carnitine trans-
porter in humans [13,14,30], rats [34,35] and mice
[18,33], because OCTN2 has the unique feature of
being the only carnitine Na-dependent high-a⁄nity
transporter within the OCT superfamily. OCTN2
transports carnitine in a Na-dependent manner,
but transports organic cations such as TEA, a pro-
totypical organic cation, in a Na-independent man-
ner, conferring one unique characteristic among the
Na-coupled organic solute transporters cloned so
far [13,14]. In renal BLM, carnitine uptake was
also a Na-dependent process but may involve a
di¡erent carrier insensitive to any of the xenobiotics
tested. In the presence of high levels of L-carnitine in
the blood, the BLM transporter may have a regula-
tory role by preventing excessive accumulation of L-
carnitine in the renal tubular cells [8]. Also, if this
transporter is multispeci¢c, it may be involved in the
¢rst step of elimination of drugs and xenobiotics in
the urine.
Our hypothesis of polarized carnitine transporters
in mouse kidney tubules was con¢rmed by Western
blot analysis, which showed that OCTN2 is localized
in BBM but not in BLM. Western blot indicated the
proteins recognized by the antibody have molecular
weights slightly over 70^80 kDa (Fig. 6) but close to
the estimated size of OCTN2 deduced from the ami-
no acid sequence (62 776 Da). This is probably refer-
able to post-translational modi¢cation (such as phos-
phorylation or glycosylation). The strong expression
of OCTN2 in kidney BBM supported its contribu-
tion to the reabsorption of carnitine from urine after
glomerular ¢ltration to maintain carnitine content in
body. Very recently, Tamai et al. [36] showed that
OCTN2 is localized on the apical membrane of renal
tubular epithelial cells in both mice and rats [36].
Valproate, a therapeutic molecule for epilepsy, in-
duced carnitine de¢ciency, and it was suggested
that the de¢ciency is related to a transporter-medi-
ated interaction between carnitine and the drug mol-
ecule [37,38]. Ohashi et al. [30] proposed that the
competitive inhibition of hOCTN2-mediated carni-
tine transport by valproate may be one of the mech-
anisms of drug-induced carnitine de¢ciency. Since we
found that valproate inhibited carnitine uptake by
renal BBM and not by BLM, we suggest that this
drug interacts with carnitine reabsorption by the
OCTN2 transporter at the BBM level in kidney.
The data do not exclude the possibility that the
drug-induced carnitine de¢ciency during long-term
treatment may be caused by inhibition of OCTN2-
mediated carnitine transport in other tissues such as
heart, skeletal muscle and liver, where OCTN2 is
also strongly expressed. This correlates with the im-
portance of carnitine function since more than 80%
of carnitine is stored in muscle [39]. Heart and skel-
etal muscle are the two tissues which largely depend
on carnitine to produce energy by long-chain fatty
acid L-oxidation. More recently, Berardi et al. [40]
have suggested the presence of the OCTN2 protein in
the skeletal muscle by determining the properties of
carnitine transport in plasma membrane vesicles
from rat muscle. Only one previous study suggested
that OCTN2 protein was present in the liver [17],
based on similar kinetic parameters (Km and Vmax)
found in cDNA OCTN2 transfected hepatocyte cul-
ture cells and membrane vesicles isolated from hepa-
tocytes. Our tissue distribution is very close to that
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obtained recently by Tamai et al. [33] on Western
blot by using antibodies raised against the divergent
COOH-terminal portions of the OCTN2 protein. So,
two di¡erent speci¢c anti-OCTN2 antibodies lead to
the same results, although Tamai et al. [33] did not
use skeletal muscle and intestine.
4.2. Characterization of L-carnitine transport in the
mouse intestine
In the mouse intestine, we found that carnitine
uptake by BBM was very low and Na-independent,
while that by BLM was relatively high, temperature-
and Na-dependent, but pH-independent (Fig. 7).
This indicates that carnitine transport systems are
also di¡erent between BBM and BLM in the mouse
intestine. All these results obtained with membrane
vesicles correlate with McCloud’s study [4] using
Caco-2 cells as an intestinal model. A Western blot
conducted in these membranes showed no immuno-
reactivity between polyclonal antibodies against
OCTN2 with intestine (homogenate fraction) (Fig.
6C) and BBM or BLM fractions (Fig. 6B), as in
brain and lungs. So, Na-dependent carnitine trans-
port in intestinal mouse BLM may be accomplished
via a transporter other than OCTN2. This is sup-
ported by our ¢nding that carnitine uptake by intes-
tinal BLM is pH-independent (Fig. 8) while a known
characteristic of mouse OCTN2 is to mediate carni-
tine transport in a pH-dependent manner [33]. In rat
intestine, a carnitine transporter called CT1 (carni-
tine transporter type 1) was cloned earlier [35] but it
corresponds to OCTN2 which is not expressed in
mouse small intestine. Our results also suggest that
there are di¡erent carnitine transporters in BBM and
BLM from intestine based on the di¡erent carnitine
uptake characteristics observed in these membranes
(Fig. 7).
In summary, the present study shows the presence
of di¡erent carrier-mediated systems for L-carnitine
at the level of mouse renal and intestinal BBM and
BLM. In kidney, carnitine uptake was Na-depen-
dent, for both membrane preparations, but in intes-
tine, it was Na-dependent only in BLM. The renal
BBM carnitine transporter is likely to be OCTN2 as
indicated by a strong reactivity with the anti-OCTN2
polyclonal antibody in Western blot, and by the sig-
ni¢cant inhibition of BBM carnitine uptake by the
drugs TEA, verapamil, valproate and pyrilamine, in
the uptake study. The tissue distribution of OCTN2
showed a broad expression pro¢le of the protein with
a strong expression in kidney, heart, skeletal muscle
and liver, but with no expression in brain, lungs and
small intestine which was in correlation with our
functional study. Therefore, OCTN2 not only plays
an important role in carnitine reabsorption in kid-
ney, but may also be involved in carnitine distribu-
tion and organic cations elimination in several tis-
sues.
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